Martha Mims is an Oncology physician affiliated with Baylor College of Medicine. OpenAlex indexes 189 publications with 3,764 citations (h-index 30); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1504 Taub Loop
Dept. Of Medicine
Houston, TX 770301608
Telephone
713-873-2000Provider last certified this registry record 24 Nov 2020.
Clinical trials
- Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Sponsor: Baylor College of Medicine
- Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide
Sponsor: Baylor College of Medicine
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Eisai Inc.Program year20251 payment
- Celgene CorporationProgram year20221 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
55.9%Kinase inhibitor21.5%Imbruvica33%Imatinib Mesylate32%Cabometyx22%Brukinsa14%Part D<11 patientsCytochrome P450 17A1 Inhibitor21.3%Abiraterone Acetate100%Part D≥11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
18.5%Corticosteroid15%Prednisone100%Part D≥12 patientsSerotonin-3 Receptor Antagonist3.5%Ondansetron Hcl100%Part D<11 patientsRespiratory
12%Opioid Agonist12%Hydrocodone-Acetaminophen100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 1985–2026 per NIH RePORTER. The latest:
- OPTIMISE: A Shared Care Approach for Improving Comprehensive Care of Cancer Patients with Comorbidities in A Safety-Net System
Baylor College of Medicine
FY2025$1R01CA258040
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Christie Ballantyne, MD
Baylor College of Medicine
Biykem Bozkurt, MD
Baylor College of Medicine
William Mitch, MD
Baylor College of Medicine
Garabed Eknoyan, MD
Baylor College of Medicine
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”